Approval to Escalate Dosing in Kidney Disease Trial
Filed with ASX · · 4 pages · English
PYC Therapeutics Limited on 6ix
Earlier from PYC Therapeutics
- Presentation of Clinical Proof of Concept in Lead Program
- Completion of Entitlement Offer
- First Subject Dosed in PKD Clinical Trial
- Placement of Shortfall
- Retail Entitlement Offer Booklet
Later from PYC Therapeutics
- SRC Approves Dose Escalation in ADOA Clinical Trial
- FDA Alignment on Registrational Trial Design RP11 Program
- Fourth Drug Program Progressing to Human Trials
- Approval to Progress Kidney Disease Trial to Next Stage
- Approval to Escalate Dosing in Kidney Disease Clinical Trial
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics